Istiratumab

Istiratumab
Monoclonal antibody
Type	?
Source	Human
Target	IGF1R, ErbB3
Clinical data
Other names	MM-141
ATC code	none;
Identifiers
CAS Number	1509928-04-4;
ChemSpider	none;
UNII	XLR461MD3M;
KEGG	D10943;
Chemical and physical data
Formula	C8802H13532N2392O2796S58
Molar mass	199458.51 g·mol−1

Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.^[1]

It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer.^[2]

References

^ Alternative Names: MM-141. "Istiratumab - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.{{cite web}}: CS1 maint: numeric names: authors list (link)
^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL : USAN (CD-106) ISTIRATUMAB" (PDF). Searchusan.ama-assn.org. Retrieved 2017-05-23.

This oncology article is a stub. You can help Wikipedia by expanding it.

[1] Alternative Names: MM-141. "Istiratumab - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.{{cite web}}: CS1 maint: numeric names: authors list (link)

[2] "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL : USAN (CD-106) ISTIRATUMAB" (PDF). Searchusan.ama-assn.org. Retrieved 2017-05-23.

[1]

[2]